


Primary treatment phase

Maintenance treatment phase

Follow-up



Cyclophosphamide pretreatment
(300 mg/m² [max 600 mg] single IV infusion)

L-BLP25 arm: 930 µg SC

Sodium chloride
(0.9% IV)


Control arm: placebo* SC

Tumour imaging**
(≤28 d prior to randomization)

Tumour imaging**
(according to local hospital standards)

*Formulated to provide the same carrier lipid matrix as L-BLP25, but without the adjuvant (monophosphoryl lipid A) and BLP25 lipopeptide.

**Computed tomography and/or magnetic resonance imaging.

 Each syringe represents four SC injections of L-BLP25 or placebo at four anatomical sites (deltoid or triceps region of the upper arms and the left and right anterolateral aspects of the abdomen).

 The syringe represents a single IV infusion of cyclophosphamide or saline substitute for cyclophosphamide.

d, days; IV, intravenous; R, randomization; SC, subcutaneous.